Sandler Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
Sell
-7,528
Closed -$2.06M 111
2017
Q2
$2.06M Buy
+7,528
New +$2.04M 0.22% 106
2014
Q4
Sell
-12,719
Closed -$2.73M 203
2014
Q3
$2.73M Sell
12,719
-7,281
-36% -$1.42M 0.13% 153
2014
Q2
$5.2M Buy
+20,000
New +$4.37M 0.22% 147

Other funds holding AXDX

Sandler Capital Management's AXDX Position: Q3 2017 in Review

Sandler Capital Management sold out of Accelerate Diagnostics (AXDX) in Q3 2017, closing a stake of 7,528 shares — an estimated $2.06M sold.

Sandler Capital Management first reported a position in AXDX in Q2 2014 and held it in 3 quarters. The position peaked at $5.2M in Q2 2014. 118 funds tracked by Wall St. Rank hold AXDX as of Q3 2017.

  • Sandler Capital Management reported no remaining Accelerate Diagnostics position as of Q3 2017 after selling out during the quarter.
  • Sandler Capital Management sold 7,528 Accelerate Diagnostics shares in Q3 2017, an estimated $2.06M.
  • Sandler Capital Management first reported a position in Accelerate Diagnostics in Q2 2014 and held it in 3 quarters.
  • Sandler Capital Management's Accelerate Diagnostics position peaked at $5.2M in Q2 2014.
  • 118 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2017.

Based on Sandler Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.